Long-term efficacy and safety results from the phase III AGILE trial

At a median follow-up of 28.6 months, patients with newly diagnosed IDH1-mutated acute myeloid leukemia receiving ivosidenib plus azacitidine in the phase III AGILE trial had significantly longer overall survival and faster, more durable hematologic recovery. Ten out of 33 evaluable patients who received ivosidenib converted to measurable residual disease negativity. There was no overall relationship between measurable residual disease negativity and survival outcomes. However, patients with <1% variant allele frequency who were measurable residual disease negative had significantly longer overall and event-free survival and longer duration of response than those with ≥1% variant allele frequency. Ivosidenib maintained its previously reported safety profile. 

This educational resource was independently supported by Servier. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.